Loading…
JAMP CEFADROXIL is a brand name for Cefadroxil, supplied as a capsule. The medicine, its uses, side effects and dosage are the same regardless of brand.
Verbatim from this product's HC label. Tap a section to expand.
JAMP
Cefadroxil (cefadroxil) is contraindicated in patients with a known hypersensitivity to the cephalosporin group of antibiotics. WARNINGS Cephalosporin antibiotics (including JAMP Cefadroxil (cefadroxil)) should be administered with great caution to patients with known hypersensitivity to the penicillins.
Clinical and laboratory evidence exists of cross–allergenicity between the penicillin and cephalosporin groups of antibiotics. There have been reports of patients who have had reactions to both classes of antibiotics (including fatal anaphylactoid reactions after parenteral administration).
JAMP Cefadroxil should be administered with caution and then only when absolutely necessary to any patient who has a history of some form of allergy, particularly to drugs. The normal flora of the colon is altered by treatment with broad spectrum antibiotics and this may permit overgrowth of clostridia.
Studies indicate that one primary cause of antibiotic– associated colitis is a toxin produced by Clostridium difficile. With the use of cephalosporins and other broad spectrum antibiotics, pseudomembranous colitis has been reported.
It is therefore important to consider its diagnosis in patients who develop diarrhea in association with antibiotic use. Mild cases of colitis may respond to drug discontinuance alone. Moderate to severe cases should be managed with fluid, electrolyte and protein supplementation as indicated.
When the colitis is not relieved by drug discontinuance or when it is severe, oral vancomycin is the treatment of choice for antibiotic–associated pseudomembranous colitis. Other causes of colitis should also be considered. Severe Cutaneous Adverse Reactions Severe cutaneous adverse reactions (SCAR) such as acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens- Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) have been reported in association with beta-lactam treatment.
When SCAR is suspected, JAMP Cefadroxil should be discontinued and appropriate therapy and/or measures should be taken.
Susceptibility/Resistance:
Development of Drug-Resistant Bacteria Prescribing JAMP Cefadroxil in the absence of a proven or strongly suspected bacterial infection is unlikely JAMP Cefadroxil Page 5 of 26 to provide benefit to the patient and risks the development of drug-resistant bacteria.
Potential for Microbial Overgrowth Prolonged use of JAMP Cefadroxil can result in the overgrowth of non–susceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, the administration of JAMP Cefadroxil should be discontinued and appropriate measures taken.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Cefadroxil in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
An alternate therapy should be instituted if an organism becomes resistant during treatment with JAMP Cefadroxil. PRECAUTIONS A MINIMUM OF 10 DAYS TREATMENT IS RECOMMENDED FOR INFECTIONS CAUSED BY GROUP A ß–HEMOLYTIC STREPTOCOCCI. Patients should be carefully monitored to detect the development of any adverse effect or other manifestations of drug idiosyncrasy.
, epinephrine, other pressor amines, or corticosteroids). 73 m2), (See DOSAGE AND ADMINISTRATION). In patients with known or suspected renal impairment careful clinical evaluation and appropriate laboratory studies should be performed prior to and during therapy, since JAMP Cefadroxil can accumulate in serum and tissues.
If JAMP Cefadroxil is to be used for long–term therapy, hematologic, renal and hepatic functions should be monitored periodically. During treatment with the JAMP Cefadroxil antibiotics, positive direct Coombs tests have been reported.
In hematologic studies or in transfusion cross–matching procedures, when antiglobulin tests are performed on the minor side or in Coombs testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be noted that a positive Coombs test may be due to the drug.
During treatment with cefadroxil, a false positive reaction for glucose in the urine may occur with Benedict's or Fehling's solution or with Clinitest tablets, but not with enzyme– based tests such as Clinistix or Tes–Tape.
Use in Pregnancy:
The safety of cefadroxil in the treatment of infections during pregnancy has not been established. Therefore, during pregnancy the administration of JAMP Cefadroxil is not recommended. If in the opinion of the attending physician, the administration of JAMP Cefadroxil is necessary, its use requires that the anticipated benefits be weighed against the JAMP Cefadroxil Page 6 of 26 possible hazards to the fetus.
Nursing Mothers:
Cephalosporin antibiotics are excreted in human breast milk and therefore, would be ingested by the neonate during breast feeding. Nursing mothers receiving JAMP Cefadroxil should discontinue breast-feeding.
ADVERSE REACTIONS Adverse reactions observed during use of cefadroxil include:
Gastrointestinal: The most frequently observed have been nausea and vomiting. The incidence and severity are dose dependent and the latter has been severe enough to warrant cessation of therapy, but infrequently. Other reactions reported were abdominal cramps, gastric upset, heartburn, gas and diarrhea.
Hypersensitivity:
Rash, swollen and running eyes, urticaria, eosinophilia, angioedema and positive direct Coombs test.
Central Nervous System:
Dizziness, weakness, drowsiness, vertigo, nervousness and headaches.
Miscellaneous:
Vaginitis, monilial vaginitis, vaginal itching, cramps in side and legs, transient neutropenia and elevations in BUN, alkaline phosphatase and AST (SGOT). 8% of patients. JAMP […]